|Bid||100.00 x 1300|
|Ask||0.00 x 1300|
|Day's range||99.65 - 105.50|
|52-week range||31.70 - 109.30|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2018 - 3 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||80.75|
Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
Foundation Medicine, Inc. today announced that new data generated from its comprehensive genomic profiling assays will be presented at the American Society of Clinical Oncology Annual Meeting from June 1-5, 2018 in Chicago.
Foundation Medicine, Inc. (FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The companion diagnostic tests will leverage FoundationOne CDx™, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay for all solid tumors incorporating multiple companion diagnostics. The companies will collaborate on the development of a pan-cancer companion diagnostic to measure MSI.
NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Front ...
Foundation Medicine, Inc. (FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for FoundationOne CDx™. FoundationOne CDx is the first FDA-approved comprehensive genomic profiling assay for all solid tumors that incorporates multiple companion diagnostics. The CMS determination confirms that FoundationOne CDx meets the criteria for classification as a new ADLT.
The Cambridge, Massachusetts-based company said it had a loss of $1.02 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Foundation Medicine today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included:
Foundation Medicine, Inc. (FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in the efficient identification of known and novel genomic and expression-based biomarkers of response for investigational and approved personalized cancer therapies, including new and existing cancer immunotherapies. “In order to maximize the potential of personalized cancer therapy, we need a comprehensive biomarker strategy that includes not only tumor mutational changes and signatures but robust readouts of gene expression, requiring deep expertise in next generation DNA and RNA sequencing,” said Vincent Miller, M.D., chief medical officer at Foundation Medicine.
April 27 (Reuters) - Dian Diagnostics Group Co Ltd : * SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB ...
Foundation Medicine, Inc., , F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. , today announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling assays into clinical patient care in mainland China.
Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration granted a Breakthrough Device designation for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay.
Foundation Medicine, Inc. today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018. The management team will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m.
Foundation Medicine, Inc. today announced the presentation of new findings at the American Association for Cancer Research Annual Meeting. The data supports the use of both tissue- and blood-based comprehensive genomic profiling to advance personalized cancer care and inform the use of targeted and immunotherapy treatment approaches.
CAMBRIDGE, Mass., April 9, 2018 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients.
Foundation Medicine, Inc. today announced that FoundationOne CDx™, the first U.S. Food and Drug Administration approved comprehensive genomic profiling assay for all solid tumors incorporating multiple companion diagnostics, is now available in the United States.
NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Foundation Medicine, Inc. today announced that the Centers for Medicare & Medicaid Services issued a final National Coverage Determination for patients who receive next generation sequencing testing with an assay that meets the coverage criteria.
Foundation Medicine, Inc. today announced that Chugai Pharmaceutical Co., Ltd. , one of Japan's leading research-based pharmaceutical companies and a member of the Roche Group, will broaden patient access to Foundation Medicine’s comprehensive genomic profiling services for individuals with advanced cancer.
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their respective liquid genomic profiling assays.
Foundation Medicine, Inc. today announced that members of the company's management team will present at Cowen & Company’s 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.m.
The Cambridge, Massachusetts-based company said it had a loss of $1.05 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...